Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.62 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.62 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.56 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366085 | 0.93 | CCR3 (0.61) | CCR3PRKAA2SIGMAR1MCHR1SLC6A12 | |
| SCHEMBL1367099 | 0.92 | DRD4 (0.61) | CCR3PRKAA2SIGMAR1MCHR1SLC6A12 | |
| SCHEMBL1364918 | 0.89 | DRD4 (0.58) | CCR3PRKAA2MCHR1DRD2DRD4 | |
| SCHEMBL1365865 | 0.88 | DRD2 (0.77) | PRKAA2SIGMAR1MCHR1SLC6A12TMEM97 | |
| SCHEMBL1365988 | 0.87 | HPGDS (0.57) | CCR3PRKAA2SIGMAR1MCHR1DRD2 | |
| SCHEMBL1367102 | 0.86 | ALDH1A1 (0.59) | CCR3PRKAA2SIGMAR1MCHR1SLC6A12 | |
| SCHEMBL1365939 | 0.86 | HPGDS (0.61) | CCR3PRKAA2MCHR1DRD2DRD4 | |
| SCHEMBL1366874 | 0.85 | DRD4 (0.62) | CCR3PRKAA2SIGMAR1MCHR1SLC6A12 | |
| SCHEMBL347916 | 0.85 | HPGDS (0.80) | CCR3DRD2DRD4HPGDS | |
| SCHEMBL1365745 | 0.85 | DRD4 (0.60) | CCR3PRKAA2SIGMAR1MCHR1SLC6A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | CCR3 440/4885PRKAA2 3883/4885SIGMAR1 2465/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | CCR3 440/4885PRKAA2 3883/4885SIGMAR1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.